Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer
| العنوان: | Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer |
|---|---|
| المؤلفون: | Seung Seop Yeom, Han Duk Kwak, Hyeong Rok Kim, Young Jin Kim, Soo Young Lee, Ji Eun Yoon, Jae Kyun Joo, Chang Hyun Kim |
| المصدر: | Annals of Coloproctology Annals of Coloproctology, Vol 35, Iss 3, Pp 137-143 (2019) |
| بيانات النشر: | Korean Society of Coloproctology, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Rectum, Rectal neoplasms, RC799-869, 03 medical and health sciences, 0302 clinical medicine, Recurrence, medicine, business.industry, Hazard ratio, Gastroenterology, Chemoradiotherapy, Diseases of the digestive system. Gastroenterology, medicine.disease, Surgery, Radiation therapy, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Propensity score matching, Cohort, T-stage, 030211 gastroenterology & hepatology, Original Article, Drug therapy, business |
| الوصف: | Purpose: The aim of this study was to assess oncological outcomes of postoperative radiotherapy plus chemotherapy (CRT) versus chemotherapy alone (CTx) in stage II or III upper rectal cancer patients who underwent curative surgery.Methods: We retrospectively reviewed 263 consecutive patients with pathologic stage II or III upper rectal cancer who underwent primary curative resection with postoperative CRT or CTx from January 2008 to December 2014 at Chonnam National University Hwasun Hospital. Multivariate and propensity score matching analyses were used to reduce selection bias.Results: Median follow-up was 48.1 months for the entire cohort and 53.5 months for the matched cohort. In subgroup analysis of the propensity score matched cohort, the 3-year local recurrence-free survival was 94.1% (95% confidence interval [CI], 87.8%–100%) in the CRT group and 90.1% (95% CI, 82.8%–97.9%) in the CTx group (P = 0.370). No significant difference in disease-free survival was observed according to treatment type. On multivariate analysis, circumferential resection margin involvement (hazard ratio [HR], 2.386; 95% CI, 1.190–7.599; P = 0.032), N stage (HR, 6.262; 95% CI, 1.843–21.278, P = 0.003), and T stage (HR, 5.896, 95% CI, 1.298–6.780, P = 0.021) were identified as independent risk factors for local recurrence of tumors of the upper rectum.Conclusion: Omission of radiotherapy in an adjuvant treatment setting may not jeopardize oncologic outcomes in stages II and III upper rectal cancer. |
| اللغة: | English |
| تدمد: | 2287-9722 2287-9714 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2780ce71347395c1781c6b5230f39b3c http://europepmc.org/articles/PMC6625770 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....2780ce71347395c1781c6b5230f39b3c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22879722 22879714 |
|---|